Internal Medicine
RSSArticles
-
FDA Issues Draft Guidance on Lowering Lead Levels in Baby Food
If plan is implemented, the agency estimates it could result in a 24% to 27% reduction in exposure.
-
Researchers Find Little Difference in Efficacy Between Top Heart Failure Treatments
In a head-to-head comparison of furosemide and torsemide, one diuretic was not significantly more efficacious than the other in improving heart failure survival rates.
-
Gaps Remain in Alcohol Use Screening Among Pregnant Patients
Despite the known benefits, it appears some clinicians still do not counsel women to avoid alcohol during pregnancy.
-
Group Publishes Guideline for Evaluating and Treating Obesity in Young Patients
American Academy of Pediatrics offers more than a dozen evidence-based key action statements to help physicians treat children and adolescents.
-
Congress Formally Ends X-Waiver Requirement
Lawmakers remove this barrier to treating opioid use disorder.
-
Is AV Block Complete?
Does the ECG in the figure represent complete AV block? If not, why not?
-
Fecal Microbiota, live-jslm (Rebyota)
Rebyota can be prescribed to prevent recurring Clostridioides difficile infection for patients age 18 years and older who are following antibiotic treatment for recurring episodes.
-
Is Screening for Atrial Fibrillation Cost Effective?
Self-screening for atrial fibrillation in elderly individuals could lead to lower stroke rates, prevent bleeding-related hospitalizations, and save money.
-
COVID-19: Beware Remdesivir Resistance
Researchers reported two immunosuppressed renal transplant recipients with persistent SARS-CoV-2 infection in association with the new emergence of mutations in RNA-dependent RNA polymerase after remdesivir treatment.
-
Triglyceride-Lowering Therapy and Cardiovascular Events
Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.